Company: IXHL
Filing Date: 2025-03-10
Form Type: 8-K
Source: 0001213900-25-022279
Chunk: 1

Company: Incannex Healthcare Inc.
Filing Date: 2025-03-10
Form: 8-K
Item: Item 1.01
Chunk 1
---
 to the product of (x) the aggregate number of shares of common stock that would be
issuable upon a cashless exercise of the Series A Warrant multiplied by (y) 3. The Pre-Funded Warrants are exercisable for shares of
Common Stock for a nominal exercise price of $0.0001 per Pre-Funded Warrant Share, are immediately exercisable upon issuance and
expire when exercised in full. The Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially
owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation
(4.99%/9.99%); provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving 61
days’ notice to the Company, but not to any percentage in excess of 9.99%.

In
connection with the Private Placement, the Company entered into a registration rights agreement with the Purchasers on March 7, 2025
(the “ Registration Rights Agreement”), pursuant to which the Company agreed to use reasonable best efforts to register
the Securities for resale within thirty (30) days of the filing date of the registration statement (or, in the event of a
“limited review” or “full review” seventy-five (75) days) and also agreed to call a special meeting of
stockholders no later than sixty (60) days following the closing of the Private Placement for the approval of (i) the issuance of the Series
A Warrant Shares and adjustments to the exercise price and shares in the Series A Warrants as required pursuant to the rules and
regulations of the Nasdaq Stock Market LLC, and (ii) for an increase in the authorized number of shares of Common Stock as may be
required for the full exercise of the Series A Warrants.

On
March 7, 2025, the Company also entered into a placement agency agreement (the “ Placement Agreement”) with R. F. Lafferty &
Co., Inc. (“ R. F. Lafferty”) as the sole placement agent in connection with the Private Placement (the “ Placement Agent”).
As compensation to the Placement Agent, the Company will pay the placement agent placement commission equal to 7.0% of the aggregate gross
proceeds from the Private Placement. In addition, the Company agreed to reimburse the placement agent for certain of out-of-pocket expenses,
including for reasonable legal fees and disbursements for its counsel as specified in the Placement Agreement